

Johannes Lorscheider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7707801/publications.pdf>

Version: 2024-02-01

26
papers

2,012
citations

623734

14
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

3059
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 81, 857-870.	5.3	768
2	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	7.6	281
3	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	10.2	210
4	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	5.3	158
5	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2015, 84, 1639-1643.	1.1	153
6	T-cell response against varicella-zoster virus in fingolimod-treated MS patients. <i>Neurology</i> , 2013, 81, 174-181.	1.1	64
7	Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 274.	9.0	56
8	Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 777-785.	3.0	46
9	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. <i>JAMA Neurology</i> , 2022, 79, 682.	9.0	41
10	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.1	38
11	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. <i>PLoS ONE</i> , 2016, 11, e0152347.	2.5	38
12	A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1682-1685.	3.0	32
13	Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment. <i>European Journal of Neurology</i> , 2020, 27, 1066-1075.	3.3	21
14	Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e30394.	4.3	21
15	Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 941-949.	3.6	16
16	The BAR Domain Protein PICK1 Regulates Cell Recognition and Morphogenesis by Interacting with Neph Proteins. <i>Molecular and Cellular Biology</i> , 2011, 31, 3241-3251.	2.3	14
17	Accurate classification of secondary progression in multiple sclerosis using a decision tree. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1240-1249.	3.0	14
18	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	3.3	12

#	ARTICLE	IF	CITATIONS
19	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. <i>Multiple Sclerosis Journal</i> , 2021, 27, 439-448.	3.0	8
20	Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials. <i>Multiple Sclerosis Journal</i> , 2020, 26, 993-996.	3.0	6
21	Endovascular Treatment for Acute Ischemic Stroke With or Without General Anesthesia: A Matched Comparison. <i>Stroke</i> , 2022, 53, 1520-1529.	2.0	6
22	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	3
23	Hypothyroidism manifesting as multiple cranial neuropathies: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 180.	0.8	2
24	PML with dimethyl fumarateâ€”No convincing case against natalizumab. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1687-1688.	3.0	1
25	Acute Polyradiculomyelitis With Spinal Cord Gray Matter Lesions: A Report of Two Cases. <i>Frontiers in Neurology</i> , 2021, 12, 721669.	2.4	1
26	When does a heap become a heap?. <i>Multiple Sclerosis Journal</i> , 2021, 27, 329-330.	3.0	0